Drug Trial Radar · NCT04650451
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
220
Planned (sponsor's estimate)
Start
Dec 7, 2020
Primary completion
Dec 31, 2025
Study completion Jan 2, 2027
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid to subjects with previously treated, locally advanced or metastatic solid tumors which are HER2 amplified/overexpressed.
Conditions
- HER-2 Gene Amplification
- HER2-positive Gastric Cancer
- HER2-positive Breast Cancer
- HER-2 Protein Overexpression
- Solid Tumor, Adult
Interventions
chimeric antigen receptor (CAR) T cell therapyBiological
HER2-targeted dual-switch CAR-T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of BPX-603Time frame: 35 days from time of BPX-603 infusion
- Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)Time frame: through Phase 1 completion, up to 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California San Diego (UCSD)
La Jolla, California
Winship Cancer Institute at Emory University
Atlanta, Georgia
University of Chicago
Chicago, Illinois
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.